Form 4: Hepion Pharmaceuticals Director Buys Shares
Insider Transaction (Form 4)
Danina Fisher, a Director of Hepion Pharmaceuticals, Inc., purchased 400,000 shares of common stock on September 29, 2026 for $0.05 per share.
Summary
- Open-market purchase: acquired 200,000 Common Stock at $0.05 ($10,000) on September 29, 2026; holds 200,000 after (Direct).
- Open-market purchase: acquired 200,000 Warrants on September 29, 2026; holds 200,000 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $10,000, committing personal capital to the stock.
Insider Transactions
Danina Fisher — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-29 | Open-market purchase | Common Stock | 200,000 | $0 | $10.0K | 200,000 |
| 2026-09-29 | Open-market purchase | Warrants | 200,000 | — | — | 200,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-29 | Open-market purchase (200,000 shares) |
| 2026-09-29 | Open-market purchase (200,000 shares) |
Keywords
insider transaction, Form 4, HEPA, Hepion Pharmaceuticals, Inc., bullish, Danina Fisher
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.